• Viatris NDA for MR-107A-02, a fast-acting meloxicam, accepted for FDA review for moderate-to-severe acute pain.
• PDUFA action date set for Dec. 27, 2026.
• Filing backed by two Phase 3 trials in post-surgical acute pain that met primary and secondary endpoints, including reduced opioid rescue use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viatris Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE61418) on May 18, 2026, and is solely responsible for the information contained therein.